You are now visiting tipharma.com.
On 1 January, 2016, TI Pharma and CTMM merged
to form a new organization called Lygature.
Please note that information on the tipharma.com site has not
been updated since, and is retained as an archive.
For up-to-date information, please visit lygature.org.
Breast and prostate cancer have a relatively high prevalence among women and men, respectively. Current treatment exists of anti hormone therapy, targeting estrogen and androgen receptors r. Initially this manner of treatment is quite effective, but in the long run many patients develop anti hormone resistance. This project aims to determine the precise mechanisms behind the development of this resistance and with this knowledge develop a new generation of highly specific medicine that works even after anti hormone resistance development.
So far a method has been developed to monitor the activity of the receptor that is the target of the therapy and which is involved in the development of anti hormone resistance, and consequently this has resulted in the identification of the enzymes involved in the development of resistance to the anti hormone therapy. This is an important step towards the development of new breast and prostate cancer drugs.
Full project title: Nuclear receptors in targeted cancer therapy: improved methods for candidate selection
Start date: November 2006
End date: January 2012
Goal: Discover new target receptors for a new generation of cancer therapy that enables patient tailored therapy without the development of drug resistance
Principal investigator: Bob van de Water
Project size: 6 FTE's
Partners: Erasmus Medical Center, Leiden University, MSD, Netherlands Cancer Institute
Wilbert Zwart (project T3-107)
Shedding Light on anti-estrogen resistance and antigen presentation through biophysical techniques
“Running public-private partnerships is a profession by itself. TI Pharma is an excellent example of how you can do this in an effective way.”
Director/Secretary of the Medicines Evaluation Board